

JCO Oncology Practice

Electronic medical record-assisted telephone follow-up of breast cancer survivors during the COVID-19 pandemic: a single institution experience.

--Manuscript Draft--

Manuscript Number:	OP.20.00643R2
Full Title:	Electronic medical record-assisted telephone follow-up of breast cancer survivors during the COVID-19 pandemic: a single institution experience.
Short Title:	Phone follow-up of breast cancer survivors in COVID-19 pandemic.
Article Type:	Original Contribution
Section/Category:	Care Delivery
Corresponding Author:	Carlo Messina, Mdl S.Chiera Hospital Trento, Italia ITALY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	S.Chiera Hospital
Corresponding Author's Secondary Institution:	
First Author:	Valeria Merz, M.D.
First Author Secondary Information:	
Order of Authors:	Valeria Merz, M.D. Antonella Ferro, MD Enrico Maria Piras, PhD Alberto Zanutto, PhD Orazio Caffo, MD Carlo Messina, MD
Order of Authors Secondary Information:	
Abstract:	<p>Background: The COVID-19 outbreak rapidly became a public health emergency and led to radical changes in patient management. From the start of the pandemic, we used electronic medical record-assisted telephone follow-up (E-TFU) of cancer survivors (CS) in order to minimise hospital exposure. The aim of this prospective study was to assess how breast cancer survivors (bCS) perceived E-TFU.</p> <p>Methods: A 15-item questionnaire was e-mailed to bCS who had been managed with E-TFU. The responses were measured using Likert-like scales and were correlated with the main characteristics of the bCS using Pearson's test.</p> <p>Results: One hundred and thirty-seven out of 343 bCS (40%) completed the questionnaire between 9 March and 2 June 2020. Their median age was 59 years. Although 80.3% of bCS were satisfied with E-TFU, only 43.8% would like to have E-TFU in the future.</p> <p>A low educational level was correlated with higher COVID-19-related anxiety ($P = 0.025$). An older age ($P = 0.002$) and a low educational level ($P < 0.0001$) were correlated with the need to be accompanied to reach the hospital. A personal history of second cancer was inversely correlated with understanding medical advice ($P = 0.015$) and the expectation of feeling relief after a follow-up visit ($P = 0.0027$). Furthermore, the pandemic phase 2 was correlated with satisfaction with E-TFU ($P = 0.010$).</p> <p>Conclusion: E-TFU was an important means of avoiding hospital contacts during the COVID-19 pandemic, and the majority of bCS in the survey were satisfied with this procedure. Further studies are needed to investigate the implementation of telemedicine even outside an emergency situation.</p>

Additional Information:	
Question	Response
Previous Publication	Publication Pending - Has this manuscript been accepted for publication or presentation at a future meeting? If so, please provide the meeting and the date of the presentation.
If so, please provide the meeting and the date of the presentation. as follow-up to " Previous Publication "	Accepted for E-Poster presentation at ESMO Virtual Congress 2020 (19-21 September 2020)
Funding Information:	

Servizio ospedaliero provinciale
Struttura Ospedaliera di Trento
Presidio ospedaliero S. Chiara
U.O. Oncologia Medica
Direttore Dr. Orazio Caffo
Largo Medaglie d'Oro, 9 – 38122 Trento
tel. 0461 902121 – fax 0461 903364

July 17th, 2020

RE: Submission of the manuscript: “**Electronic medical record-assisted phone follow-up of breast cancer survivors during the COVID-19 pandemic: a single institution's experience.**”

Dear Editor,

Enclosed please find our manuscript entitled “**Electronic medical record-assisted phone follow-up of breast cancer survivors during the COVID-19 pandemic: a single institution's experience.**” for consideration for publication as Original Contribution in *JCO Oncology Practice*.

The COVID-19 outbreak rapidly became a public health emergency and led to radical changes in patient management.



Azienda con sistema di gestione certificato BS OHSAS 18001:2007



Since 2009, our team published in *Annals of Oncology* 7 years' experience with an electronic oncological patient record for the management of cancer patients (Galligioni E. et al., DOI: [10.1093/annonc/mdn567](https://doi.org/10.1093/annonc/mdn567)).

From the start of the pandemic, we used electronic medical record-assisted phone follow-up (EMR-PFU) of cancer survivors (CS) in order to minimise hospital exposure. The aim of this prospective study was to assess how breast cancer survivors (bCS) perceived E-PFU.

A 15-item questionnaire was e-mailed to bCS who had been managed by means of EMR-PFU. The responses were measured using Likert-like scales, and their correlations with the main characteristics of the bCS were evaluated using Pearson's test.

The majority of bCS in the survey were satisfied with this procedure. These results suggest that routine E-PFU could be considered even outside a situation of emergency.

To the best of our knowledge, this is the first report of the use of the EMR-PFU of bCS during the COVID-19 pandemic, and the findings suggest a need for further investigations into the reasons behind the preference for standard face-to-face follow-up visits in order to identify strategies that would increase the willingness of bCS to undergo E-PFU.

Moreover, the idea of “emergency” requires further investigation in order to evaluate whether it is only strictly applicable to life-threatening situations such as a pandemic or could also apply to less serious events (e.g. avoiding the hospital during the influenza season) or personal limitations such as the impossibility of attending a hospital appointment because of a broken leg or a malfunctioning car.



We really hope that you could consider our manuscript for publication and we greatly appreciate your review of our manuscript.

We confirm that this manuscript has not been published elsewhere and is not under consideration by any other journal.

All the authors have contributed to the manuscript and agree with this submission to *JCO Oncology Practice* and have no conflicts of interest to declare.

All the respondents gave their informed consent to completing the questionnaire, the answers to which were analysed by authors and matched with the clinical data retrieved from the web-based EMR.

We would recommend three reviewers to review our manuscript: Antonio Di Meglio (Institut de Cancérologie Gustave Roussy), Ines Maria Vaz Duarte Luis (Institut de Cancérologie Gustave Roussy), Arlindo Ferreira (Fundação Champalimaud).

Thank you very much for your consideration. We look forward to hearing from you about the destiny of our letter.

Sincerely,

Carlo Messina

Carlo Messina, MD

e-mail: carlo.messina@apss.tn.it

phone: 0039-3339540076



Reviewer 1: I appreciated to review a revised version of the the manuscript titled "Electronic medical record-assisted phone follow-up of breast cancer survivors during the COVID-19 pandemic: a single institution's experience" submitted by Valeria Merz and colleagues for consideration in JCO Oncology Practice.

I would like to thank the authors for taking the time to thoroughly respond to my comments and carefully address them in the revised version of the manuscript. I also would like to congratulate them for this major revision of their work. Overall, the major limitations that I had highlighted in the first round of revision are now acknowledged and addressed in the revised manuscript discussion section. Some of the comments of reviewer 2 were aligned with mine and they were also addressed.

I have a couple of additional minor remarks/clarifications to ask:

- Thanks for clarifying that the questionnaire was emailed to 265 patients that had an email address and that 137 among them responded to the questionnaire. Therefore, I believe you should report a response rate of $137/265=51.7\%$ and I am not sure why your reported response rate is 48.4%. Please clarify this.

Thank you for your comment. We have modified the exact percentage number.

- Final paragraph of results, specify that you are presenting univariate p-values in the manuscript main text and Table 2.

We have added that the results presented have been obtained at the univariate analysis.

- Authors added a supplementary Table S1 with results of a multivariate analysis to accommodate for multiple determinants. Please note that this should be called Table S1 (as you have in the manuscript text, as opposed to Table 2 as you have now in the Tables section).

Thank you, we modified the title in Table S1.

What type of multivariate analysis was this? Please add this clarification to methods and to Table S1.

We performed Chi square test. We specified to have performed a multivariate analysis in Methods section and we added this information in Table S1.

- Table 2. Specify in a footnote that you present p-values and you provide correlation coefficients in brackets.

We added this information in the caption.

- Check for consistency of wording throughout the manuscript (eg, survey vs. questionnaire).

Thank you for suggesting this clarification. We replaced questionnaire with survey.

- Please note that in the Discussion section the sentence "Anyway, patients that would accept to be visited remotely in a non-emergency situation represent a significant subgroup and deserve further evaluations." is repeated twice.

We removed one sentence.

- Finally, in Methods authors state that they identified consecutive breast cancer survivors

"with no evidence of active disease", and in the rebuttal letter they also state that "Our study is focalised on breast cancer survivors, so we only included patients with no evidence of disease and who completed their eventual chemotherapy or target therapy. The only active treatment was the hormone therapy which was not stopped during pandemic." However, in Table 1, authors have 2 patients with stage IV breast cancer among respondents to the survey, who were therefore included in the analyses. Please confirm that these 2 patients did not have active disease and were not undergoing active treatment other than hormone therapy at the time of this analysis.

We confirm that all the patients have no active disease. In particular, the two stage IV breast cancer patients had had an oligometastatic disease, treated also with local treatments, and subsequent no evidence of disease.

Original contribution

Electronic medical record-assisted telephone follow-up of breast cancer survivors during the COVID-19 pandemic: a single institution experience.

Valeria Merz^a, Antonella Ferro^a, Enrico Maria Piras^b, Alberto Zanutto^b, Orazio Caffo^a, Carlo Messina^{a*}.

^aDepartment of Medical Oncology, Santa Chiara Hospital, Trento, Italy; ^bCentre for Information and Communication Technology, Bruno Kessler Foundation, Trento, Italy.

***Corresponding author:** Department of Medical Oncology, Santa Chiara Hospital, Largo Medaglie d'Oro 9, 38122 Trento, Italy. Tel. +39-3339540076. E-mail: carlo.messina@apss.tn.it

Acknowledgements: The authors would like to thank all of the patients and their families for participating in this study and for their collaboration during the COVID-19 pandemic.

Running head: Telephone follow-up of breast cancer survivors in COVID-19 pandemic.

ABSTRACT

Background: The COVID-19 outbreak rapidly became a public health emergency and led to radical changes in patient management. From the start of the pandemic, we used electronic medical record-assisted telephone follow-up (E-TFU) of cancer survivors (CS) in order to minimise hospital exposure. The aim of this prospective study was to assess how breast cancer survivors (bCS) perceived E-TFU.

Methods: A 15-item survey was e-mailed to bCS who had been managed with E-TFU. The responses were measured using Likert-like scales and were correlated with the main characteristics of the bCS using Pearson's test.

Results: One hundred and thirty-seven out of 343 bCS (40%) completed the survey between 9 March and 2 June 2020. Their median age was 59 years. Although 80.3% of bCS were satisfied with E-TFU, only 43.8% would like to have E-TFU in the future.

A low educational level was correlated with higher COVID-19-related anxiety ($P=0.025$). An older age ($P=0.002$) and a low educational level ($P<0.0001$) were correlated with the need to be accompanied to reach the hospital. A personal history of second cancer was inversely correlated with understanding medical advice ($P=0.015$) and the expectation of feeling relief after a follow-up visit ($P=0.0027$). Furthermore, the pandemic phase 2 was correlated with satisfaction with E-TFU ($P=0.010$).

Conclusion: E-TFU was an important means of avoiding hospital contacts during the COVID-19 pandemic, and the majority of bCS in the survey were satisfied with this procedure. Further studies are needed to investigate the implementation of telemedicine even outside an emergency situation.

INTRODUCTION

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was a public health emergency before the World Health Organisation declared it to be a pandemic on 11 March 2020 [1]. First China, and then (by the end of February 2020) Italy experienced the rapid and uncontrolled spread of the virus, and a steep increase in the number of new cases and deaths [2], with recorded lethality being higher in Italy than in China (9% vs 4.3%) [3, 4]. Although the severity of the illness and the risk of death seem to be associated with old age and pre-existing co-morbidities such as cardiopulmonary disease, diabetes and immunodepression, cancer patients and cancer survivors (CS) may be additional high-risk categories [5, 6]. A cohort study of 928 patients from the USA, Canada and Spain with active or previous cancer (45% of the total population) and confirmed SARS-CoV-2 infection entered in the database of the COVID-19 and Cancer Consortium (CCC19) revealed a high 30-day all-cause mortality rate of 13% [7].

Italian lockdown comprised two consecutive phases. The phase 1 started on 9 March 2020 and consisted of absolute prohibition of leaving home except for going to work or other valid reasons (e.g buy essential goods, go to the hospital) [8]. The phase 2 lasted from 4 May to 1 June 2020 and opened up the chance to visit relatives within the own region and do physical activity outdoor. In both the phases almost all stores, cafes and restaurants were closed.

Given that hospitals were considered places at risk of spreading the infection, there was a strong desire to minimise the presence of cancer patients by introducing new telemedicine strategies for follow-up (FU) examinations. This clearly requires robust information technology support in order to allow clinicians to retrieve a record of a patient's clinical history easily and rapidly. Since June 2000, our oncology unit has been using a web-based electronic medical record (EMR) to collect all of the clinical data, laboratory test results, and the findings of imaging examinations and pathology reports relating to each of our patients [9]. This proved to be invaluable when we decided to replace

standard FU visits with EMR-assisted telephone follow-up (E-TFU) interviews for all cancer survivors (CS) at the beginning of the COVID-19 pandemic.

The aim of this prospective study was to assess how E-TFU is perceived by breast CS (bCS), who represent the large majority of the patients followed up at our unit.

MATERIAL AND METHODS

From 9 March 2020 (the start of the Italian government's phase 1 of the COVID-19 pandemic), we switched our in-person follow-up visits to E-TFU, exploiting our web-based EMR that collects the entire medical history of patients and enables to look at the laboratory test results, imaging and pathology reports, and all medical consultations performed in our region. For the purpose of the present study, we identified all of the consecutive bCS who underwent E-TFU until 2 June 2020 (the end of phase 2) with no evidence of active disease. Previous chemotherapy or biological therapy and previous or ongoing endocrine therapy were permitted.

We collected data of bCS relating to their age, sex and educational level; their personal history of a second cancer (previous breast cancer or other tumor types) and family history of cancer; the dates of diagnosis and surgery; the molecular subtype of the tumour; exposure to chemotherapy in a neoadjuvant or adjuvant setting; exposure to endocrine therapy; the duration of FU; and pre-existing co-morbidities.

All bCS providing an e-mail address received a 15-item survey covering demographic information, COVID-19 or breast cancer-related anxiety, satisfaction with the E-TFU, and willingness to accept E-TFU in the future for non-emergency situations. The survey was prepared by EMP and AZ, and an English translated version is reported in the Appendix. Five-point ordinal Likert-like scales were used to rate the extent of agreement or disagreement with the multiple statements [10]. A score from 1 to 5, corresponding to the five possible answer options, describes an increasing level of agreement. Older or less tech-savvy patients were encouraged to ask for support of other family members, that if necessary have been directly contacted.

The respondents gave their informed consent to completing the survey, the answers to which were analysed by VM and CM and matched with the clinical data retrieved from the web-based EMR.

The primary aim of this prospective study was to assess the acceptance of the E-TFU. The secondary aims were to assess the respondents' perception of their understanding of the medical

advice received during the E-TFU, their satisfaction with the possibility of asking for clarifications, and their reaction to the possible future use of the system in a non-emergency setting.

The continuous variables are expressed as median values and ranges, and the categorical variables as absolute numbers and percentages. The differences in the baseline characteristics of the respondents and non-respondents to the survey were analysed using Fisher's exact test and the Mann-Whitney U test. The distribution of the responses evaluated with Likert-like scales and possible correlations with the bCS demographic and clinical characteristics were compared at uni- and multivariate analyses using Pearson's two-sided test and Chi square test [11]. The statistical analyses were made using SPSS, version 25.0 (IBM Corporation, Chicago, IL, USA).

RESULTS

Three hundred and forty-three bCS underwent E-TFU between 9 March and 2 June 2020, among them 78 patients declared to have not an e-mail address for the survey. The survey was completed by 137 (51.6% of surveyed). Table 1 shows the characteristics of the respondents and non-respondents. The median age of the respondents was 59 years (range 34-86). The majority of respondents (66%) completed the survey during phase 1 of the COVID-19 pandemic. The median duration of FU from the date of diagnosis was 46 months (range 2-134 months). About two-thirds of the respondents had a high school diploma or university degree. Ninety-six (70%) had a positive family history of cancer, and 27 (20%) a personal history of a second cancer: 20 had a previous breast cancer and the other 7 had different types of cancer (e.g. colon or renal cancer). Forty-three percent had pre-existing co-morbidities. Sixty-five (47%) received chemotherapy in a neoadjuvant or adjuvant setting. The majority (83%) had received adjuvant endocrine therapy, which was ongoing in 64%. The median time from the end of chemotherapy and the PFU was 42 months (range 5-208 months).

Most of the bCS (80%) were capable of reaching the hospital autonomously for standard FU visits. About 60% lived in the suburbs, and 40% in the city centre. The median time from the last standard FU visit to the E-TFU was six months (range 1-42).

Nearly 64% of the respondents suffered from COVID-19-related anxiety about their health, the majority of whom (83%) were looking forward to the FU visit to feel relief (Supp. Fig. S1). Before the E-TFU, 68% thought that it would have been easy to undergo E-TFU instead of standard FU. Almost all of the respondents (97.1%) believed that they had understood the medical advice received during the E-TFU, and 93.4% agreed that the E-TFU doctors had understood their needs, 89.8% were satisfied with the duration of the phone call, and 90.5% agreed that they had had an opportunity to ask for clarifications. Ninety-two percent agreed with the medical decision to replace the standard FU visit with E-TFU in absence of a real sign of emergency in order to minimise hospital exposure, but only 43.8% said that they would like to have a future E-TFU in a non-emergency situation. The latter subgroup of patients had a median age of 62 years and among them 10% had a previous cancer, the majority (68.3%) had an early stage breast cancer (0 or I stage), 40% had received chemotherapy and 80% had received or was receiving endocrine therapy. Overall, 80.3% of the respondents were satisfied when comparing E-TFU with a standard FU visit. Tables 2 and S1 show the correlations between the patients' clinical characteristics and their answers to the survey.

At the univariate analysis a low educational level was correlated with higher COVID-19-related anxiety ($P=0.025$). An older age ($P=0.002$) and a low educational level ($P<0.0001$) were correlated with the need to be accompanied to reach the hospital. A personal history of second cancer was inversely correlated with understanding medical advice ($P=0.015$) and the expectation of feeling relief after a FU visit ($P=0.0027$). Furthermore, the pandemic phase 2 was correlated with satisfaction with E-TFU ($P=0.010$). No clinical characteristics were correlated with the willing to undergo E-TFU in the future.

DISCUSSION

Italy was the first European country to be hit by the COVID-19 outbreak which, as of 1 June 2020, had led to 233.607 confirmed cases and 32.235 deaths [12,13]. The unexpected and rapid spread of SARS-CoV-2 left many oncologists facing unprecedented challenges.

Liang et al. first showed that cancer patients were at increased risk of SARS-CoV-2 infection and the severe consequences that often require admission to an intensive care unit [6]. This led Italian Association of Medical Oncology (AIOM) and the Boards of Academic Oncologists (COMU) and Oncology Unit Directors (CIPOMO) to make specific recommendations concerning cancer patients receiving active treatments during the outbreak, CS undergoing FU, and the hospital visits of patients and their caregivers [14]. Oncologists were invited to consider delaying active treatment administration in responders or administering different schedules in order to minimise hospital visits, and the outpatients scheduled for treatment who had respiratory symptoms or fever were to be triaged by nurses before hospital admission in order to prevent contact with other patients. The admission of family members or patients' caregivers was to be prohibited, except in the case of patients who seriously needed assistance.

A number of hospitals adopted E-TFU or the on-line exchange of clinical documentation instead of standard consultancy in order to reassure CS by avoiding hospital exposure except in the case of an emergency or laboratory and/or imaging signs of recurrent cancer [15]. In this context, it is worth noting that a recent Cochrane review has shown the effectiveness of telephone symptom management and highlighted the need for further research [16].

Accordingly, during pandemic we switched all our follow-up visits to telemedicine exploiting the availability of a web-based EMR, which we used since June 2000 to manage our cancer patients and which was previously described [9]. Clearly the availability of a robust EMR is crucial in supporting telemedicine activities allowing clinicians full retrieval of patients' clinical data.

All of our CS were managed by means of E-TFU during the pandemic, but this study only considers

bCS because they represent the vast majority of the CS undergoing FU at our unit. This allows us to analyse a homogeneous population but clearly limits the applicability of our results to different cancer populations, since the cancer type diagnosis could impact on preference for surveillance modalities [17].

Cancer-related fatigue and cognitive disorders are distressing and highly prevalent long-term side effects among bCS, especially those who have received chemotherapy [18, 19], and so it was important to assess whether COVID-19 was a further cause of anxiety and whether E-TFU was a sufficiently good means of offering them reassurance and relief from the distress caused by the risk of infection due to hospital exposure and the risk of cancer recurrence.

Most of the respondents to our survey agreed with the use of E-TFU instead of a standard FU visit, but 48.9% disagreed with the future use of E-TFU in non-emergency situations. The majority believed they had understood the doctors' advice received during E-TFU, and were satisfied with the time and the opportunity to ask for clarifications. These findings indicate that E-TFU was a useful strategy during the COVID-19 outbreak and that it will probably be well accepted by bCS in the event of further waves of the pandemic. Although the majority of patients would prefer standard consultations in non-emergency situations, 43.8% agreed that they would be willing to undergo E-TFU in the future. The difference between these two aspects might suggest that many patients only need to get used to this novel visit modality.

It is clear that the acceptance and compliance about an innovative approach, that switches the traditional in-person visits into a telephone-based contact, might be not so immediate and a not negligible number of patients considers as not acceptable this change outside of an emergency scenario. Thus, in our opinion, the rate of patients indicating an interest in maintaining such approach in the future is not so trivial and conversely it could be surprising to find significantly higher rates after only one first experience.

Anyway, patients that would accept to be visited remotely in a non-emergency situation represent a significant subgroup and deserve further evaluations.

It is difficult to explain the relatively low level of overall satisfaction with E-TFU. Although all of the dimensions related to satisfaction indicated a much higher approval rate (89,8% approved of the duration of E-TFU; 90.5% were satisfied with the opportunity to ask for clarifications; 97% understood the medical advice received; and 93.4% felt that the doctors understood their needs), “only” 80.3% declared that they were satisfied in general. More research is required to investigate whether there are other relevant dimensions not addressed by the survey or whether there are some needs that are not met by the present form of E-TFU.

Interestingly, E-TFU has not only prevented patient access to the hospital during the pandemic, but has also allowed physicians with risky conditions working from home.

Almost all respondents affirmed that they had understood medical information during the E-TFU. Several studies report that the patient self-assessment of comprehension during a medical visit differs from a more objective assessment [20]. Obviously, this is a limitation intrinsic to the verbal communication, not confined to telephone-based visits. However, the absence of the non-verbal communication in E-TFU could increase the gap between medical communication and patient comprehension, that could be filled with video visits [21].

This study has a number of limitations related to the heterogeneity of the patients' characteristics, the duration of FU and the differences in the exposure to chemotherapy or endocrine therapy. The two groups of respondents and non-respondents had a similar number of patients by stage and endocrine treatment, but the respondents were characterised by greater exposure to chemotherapy (47.4 % vs 28.4 %, $P<0.001$) and a larger proportion of subjects with a positive family and personal history of cancer (respectively 70% vs 58%, $P=0.028$; and 19.7% vs 9.2%, $P=0.009$).

Another critical issue was the poor response rate (51.6%), which was partially due to age and the fact that not all of our CS have an e-mail address. Although failure to respond to a satisfaction survey might itself represent a signal of poor satisfaction with the offered type of FU, we cannot exclude that by contrast the most unsatisfied patients answered our survey. In fact, in presenting the

survey to the patients, we emphasized the importance to give their own opinion through the completion of the survey, even more in the case of concerns regarding the E-TFU.

Moreover, we decided not to reach out the non-respondents by a new phone contact in order to do avoid possible evaluation biases.

Furthermore, we only considered bCS, and further studies are needed before generalizing our findings to all CS. Several studies reported that telematic visits could replace in-person visits in different chronic pathologies, demonstrating a similar efficacy [22, 23, 24, 25]. Few studies investigated the use of telemedicine for cancer surveillance. A previous study reported a good acceptance of telephone FU by cured breast cancer patients without physical or psychological disadvantage compared to hospital FU [26]. A recent survey on cancer patients in surveillance after curative surgery showed that roughly 50% patients preferred to receive news about “normal” results electronically (through an electronic tool or by e-mail) while the majority of them preferred a direct conversation by in-office appointments or phone calls in the case of abnormal results [17].

Another important limitation of our study is that psychometric properties of the scales used in the survey were not previously validated. Lastly, since the analysis included a small number of patients our results and the interpretation of uni- and multivariable analyses should be cautiously considered.

Nevertheless, to the best of our knowledge, this is the first report of the use of the EMR-based E-TFU of bCS during the COVID-19 pandemic, and the findings suggest a need for further investigations into the reasons behind the preference for standard face-to-face FU visits in order to identify strategies that would increase the willingness of bCS to undergo E-TFU. For example, studies of different clinical conditions have shown show that patients prefer FU video calls over phone calls [27, 28], which suggests that a small investment in the integration of existing technologies could provide significant benefits. A review of studies of patients with chronic diseases (who have much in common with bCS) has found that video consultations can be considered an appropriate means of confronting the emergency due to COVID-19 [29].

Moreover, the idea of “emergency” requires further investigation in order evaluate whether it is only strictly applicable to life-threatening situations such as a pandemic or could also apply to less serious events (e.g. avoiding the hospital during the influenza season) or personal limitations such as the impossibility of attending a hospital appointment because of a broken leg or a malfunctioning car.

CONCLUSIONS

E-TFU proved to be an important means of avoiding hospital contacts during the COVID-19 pandemic, and the majority of our responding bCS were satisfied with the procedure. However, the number of bCS willing to have E-TFU in non-emergency situations suggests that routine E-TFU needs further investigation, at least in a subset of CS. Prospective randomised trials are warranted to assess the clinical reliability of E-TFU in comparison with standard FU visit before implementing telemedicine in everyday clinical practice. Furthermore, we only considered bCS, and further studies are needed before our findings can be generalised to all CS.

REFERENCES

1. The World Health Organization (WHO). Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. Accessed 22 March 2020.
2. Lazzarini M, Putoto G. COVID-19 in Italy: momentous decisions and many uncertainties. *Lancet Glob Health* 2020 ;8(5):e641- e642.
3. The World Health Organization (WHO). Health emergency dashboard. Available at: <https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd>. Accessed 19 March 2020.
4. <http://www.protezionecivile.gov.it/attivita-rischi/rischio-sanitario/emergenze/coronavirus>
5. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395: 1054-1062.
6. Liang W, Guan W, Chen R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020; 21: 335-337.
7. Kuderer NM, Choueiri TK, Shah DP et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet*. 2020;S0140-6736(20)31187-9
8. <http://www.governo.it/it/coronavirus-misure-del-governo>
9. Galligioni E, Berloffia F, Caffo O et al. Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years' experience. *Ann Oncol*. 2009;20(2):349- 352.
10. Sullivan GM, Artino AR Jr. Analyzing and interpreting data from likert-type scales. *J Grad Med Educ*. 2013;5(4):541- 542.
11. Wilson EB, Hilferty MM. The Distribution of Chi-Square. *Proceedings of the National Academy of Sciences of the United States of America*. 1931;17(12):684-8.

12. Istituto Superiore di sanità. Available: <https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati>.
13. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next?. *Lancet*. 2020;395(10231):1225- 1228.
14. Rischio infettivo da Coronavirus COVID-19: indicazioni per l'Oncologia da parte del Presidente AIOM, del presidente eletto AIOM, del Presidente CIPOMO e del Presidente COMU. Available at https://www.aiom.it/wa-content/uploads/2020/03/20200313_COVID19_indicazioni_AIOM-CIPOMO-COMU.pdf
15. Tagliamento M, Lambertini M, Genova C et al. Call for ensuring cancer care continuity during COVID-19 pandemic. *ESMO Open*. 2020;5(3):e000783.
16. Ream E, Hughes AE, Cox A et al. Telephone interventions for symptom management in adults with cancer. *Cochrane Database Syst Rev*. 2020;6:CD007568. Published 2020 Jun 2.
17. Onuma AE, Palmer Kelly E, Chakedis J et al. Patient preferences on the use of technology in cancer surveillance after curative surgery: A cross-sectional analysis. *Surgery* 2019 Apr;165(4):782-788
18. Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatments. *Nat Rev Clin Oncol*. 2014;11(10):597- 609
19. Joly F, Lange M, Dos Santos M et al. Long-Term Fatigue and Cognitive Disorders in Breast Cancer Survivors. *Cancers* 2019, 11, 1896.
20. Carey M, Herrmann A, Hall A et al. Exploring health literacy and preferences for risk communication among medical oncology patients. *PLoS One*. 2018 Sep 18;13(9):e0203988
21. Powell RE, Henstenburg JM, Cooper G et al. Patient Perceptions of Telehealth Primary Care Video Visits. *Ann Fam Med* 2017 May;15(3):225-229
22. Armstrong AW, Ford AR, Chambers CJ et al. Online Care Versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial. *J Invest Dermatol* 2019 May;139(5):1037-1044

23. Armstrong AW, Chambers CJ, Maverakis E et al. Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial. *JAMA Netw Open* 2018 Oct 5;1(6):e183062
24. Portnoy JM, Waller M, De Lurgio S et al. Telemedicine is as effective as in-person visits for patients with asthma. *Ann Allergy Asthma Immunol* 2016 Sep;117(3):241-5
25. Inglis SC, Clark RA, McAlister FA et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. *Cochrane Database Syst Rev* 2010 Aug 4;(8):CD007228
26. Beaver K, Tysver-Robinson D, Campbell, Twomey MM et al. Comparing hospital and telephone follow-up after treatment for breast cancer: randomised equivalence trial. *BMJ* 2009 Jan 14;338:a3147
27. Kim S S, Darwish S, Lee S A et al. A randomized controlled pilot trial of a smoking cessation intervention for US women living with HIV: telephone-based video call vs voice call. *International journal of women's health* 2018, 10, 545
28. Cohen F, McCarthy J, Gribko et al. Abstract WP329: Video Conferencing is the Preferred Method for Follow-up Communication for Post-hospital Stroke Patients. *Stroke* 2016, 47(suppl_1), AWP329-AWP329.
29. Greenhalgh T, Wherton J, Shaw S et al. Video consultations for covid-19. *BMJ* 2020;368:m998

Table 1. Baseline clinical characteristics of the respondents and non-respondents.

	Respondents n =137	Non-respondents n =206	P value
Sex			
Female	136 (99.2%)	204 (99.0%)	0.454
Male	1 (0.7%)	2 (1.0%)	
Median age (years)	59 (34-86)	63 (34-89)	0.028*
Family history of cancer	96 (70.1%)	122 (58.9%)	0.028*
Personal history of a second cancer	27 (19.7%)	19 (9.2)	0.009*
Residence			
City centre	55 (40.1%)	90 (43.5%)	0.577
Suburbs	82 (59.9%)	116 (56%)	

Stage			
0	2 (1.5%)	2 (1%)	0.380
I	71 (51.8%)	102 (49.3%)	
II	45 (32.8%)	82 (39.6%)	
III	14 (10.2%)	20 (9.7%)	
IV	2 (1.5%)	0	
Molecular subtype			0.623
Luminal A	74 (54%)	124 (59.6%)	
Luminal B/HER2-	27 (19.7%)	38 (18.3%)	
Luminal B/HER2+	15 (10.9%)	21 (10.1%)	
HER2+	6 (4.4%)	9 (4.3%)	
Triple negative	13 (9.5%)	12 (5.8%)	
Previous surgery	137 (100%)	206 (100%)	-
Previous chemotherapy	65 (47.4%)	59 (28.4%)	0.000*
Previous endocrine therapy	113 (82.5%)	174 (83.7%)	0.656
Ongoing endocrine therapy	88 (64.2%)	131 (63.3%)	1.000
Pandemic phase			0.010*
1	91 (66.5%)	108 (52.5%)	
2	46 (33.5%)	98 (47.6%)	

*statistically significant

Table 2. Correlation between clinical and biological bCS characteristics at the univariate analysis. *P* values are reported. *P* values <0.05 were considered statistically significant. Correlation coefficients are reported in brackets. Significant values are bold.

	Age	Educational level	Pandemic phase	Residence	Family history of cancer	Personal history of second cancer	Time from diagnosis	Stage	Previous chemotherapy	Time from end of chemotherapy or anti-Her2 therapy	Previous endocrine therapy	Ongoing endocrine therapy	Time from last physical follow-up
Do you usually need to be accompanied when you attend the clinic?	0.002 (0.256)	<0.001 (-0.416)	0.628 (-0.042)	0.123 (0.132)	0.911 (-0.010)	0.178 (0.116)	0.646 (-0.040)	0.660 (0.038)	0.112 (-0.136)	0.666 (-0.055)	0.684 (0.042)	0.874 (0.053)	0.518 (-0.017)
Are you anxious about your health in this emergency situation due to COVID-19?	0.447 (0.065)	0.025 (-0.191)	0.659 (-0.038)	0.750 (-0.027)	0.479 (-0.061)	0.208 (-0.108)	0.832 (-0.018)	0.663 (-0.008)	0.306 (-0.088)	0.770 (0.037)	0.158 (-0.121)	0.465 (-0.063)	0.931 (-0.007)
Do you look forward to the periodic follow-up visits to feel relief?	0.641 (-0.016)	0.295 (-0.128)	0.808 (-0.007)	0.294 (0.104)	0.855 (0.020)	0.027 (-0.189)	0.276 (-0.094)	0.476 (-0.084)	0.649 (0.039)	0.796 (-0.033)	0.834 (-0.014)	0.275 (0.052)	0.103 (-0.070)
Before the interview, do you thought it would be easy to have a phone follow-up consultation?	0.658 (-0.038)	0.056 (0.158)	0.877 (0.013)	0.355 (-0.088)	0.151 (-0.102)	0.147 (-0.115)	0.946 (-0.006)	0.772 (-0.060)	0.369 (-0.083)	0.286 (0.135)	0.310 (0.087)	0.875 (0.014)	0.682 (0.030)
During the follow-up phone call, could you clearly understand the doctor's advice/recommendation?	0.063 (-0.159)	0.055 (0.164)	0.115 (0.135)	0.526 (-0.055)	0.363 (-0.078)	0.015 (-0.207)	0.569 (0.049)	0.979 (0.002)	0.924 (0.008)	0.728 (0.044)	0.266 (0.096)	0.333 (0.083)	0.208 (0.108)
During the follow-up phone call, did you feel that the doctor understood your needs?	0.463 (-0.070)	0.545 (0.052)	0.062 (0.160)	0.309 (-0.088)	0.572 (-0.049)	0.424 (-0.069)	0.745 (-0.028)	0.798 (-0.022)	0.263 (-0.096)	0.946 (-0.009)	0.222 (0.105)	0.477 (0.061)	0.611 (-0.044)
Did the follow-up phone call allow you enough time to clarify everything useful to my situation at the	0.305 (-0.088)	0.315 (0.087)	0.063 (0.159)	0.094 (-0.143)	0.723 (0.031)	0.668 (-0.037)	0.699 (0.033)	0.525 (-0.055)	0.581 (-0.048)--- --	0.510 (0.084)	0.413 (0.071)	0.555 (0.051)	0.390 (0.074)

moment?													
During the phone call, did you have an opportunity to ask questions and ask for clarifications related to your condition?	0.173 (-0.117)	0.280 (0.093)	0.141 (0.127)	0.155 (-0.122)	0.546 (0.052)	0.106 (-0.139)	0.173 (-0.117)	0.324 (-0.086)	0.748 (0.028)	0.531 (-0.080)	0.133 (0.129)	0.107 (0.138)	0.721 (-0.031)
In the absence of a clear clinical need, were you pleased to be able to avoid going to the hospital for a standard follow-up visit?	0.759 (0.026)	0.374 (-0.077)	0.956 (-0.005)	0.985 (-0.002)	0.170 (-0.118)	0.201 (-0.110)	0.508 (-0.057)	0.370 (-0.078)	0.517 (-0.056)	0.811 (-0.030)	0.572 (-0.049)	0.976 (0.003)	0.305 (0.088)
In the absence of an urgent clinical need, would you like phone follow-ups in the future instead of going to the hospital?	0.477 (0.061)	0.271 (-0.095)	0.159 (0.121)	0.827 (-0.019)	0.639 (-0.040)	0.0112 (-0.136)	0.852 (-0.016)	0.059 (-0.164)	0.082 (-0.149)	0.530 (0.080)	0.795 (0.022)	0.479 (-0.061)	0.304 (0.088)
Overall, in comparison with a standard follow-up visit, how satisfied were you with the phone call?	0.968 (0.003)	0.567 (-0.049)	0.010 (0.219)	0.818 (-0.020)	0.311 (-0.087)	0.133 (-0.129)	0.856 (0.016)	0.840 (-0.018)	0.111 (-0.137)--- --	0.280 (-0.137)	0.095 (0.143)	0.284 (0.092)	0.525 (0.055)

Appendix

Web-based electronic medical record-assisted phone follow-up during the COVID-19 pandemic: a survey.

Dear Sir/Madam,

As you know, the coronavirus epidemic forced us to use the phone to carry out our periodic follow-up evaluations for the first time.

It is important for us to know what you think of this experience, and whether you found it positive and satisfactory in terms of the various aspects covered by your interview with the doctor.

For this reason, we are sending you a short survey in order to evaluate your agreement with this method of contact.

None of the questions relate to sensitive information. Your answers will be anonymised and then analysed in aggregate form in such a way as to make it impossible to trace them back to you.

If you are willing to respond to the survey, please click on the link at the bottom of this e-mail.

In the case of any difficulty, do not hesitate to contact us at the following e-mail addresses: valeria.merz@apss.tn.it or carlo.messina@apss.tn.it.

Thank you once again for your contribution.

The doctors of the Oncology Unit, Santa Chiara Hospital, Trento, Italy.

Section 1

Thank you very much for agreeing to participate in this survey. Completing the survey only takes a few minutes, but it will allow us to evaluate the phone follow-up visit. The data will only be used for research purposes, and will be processed in aggregate form in order to guarantee the privacy of the respondents.

- Date of birth (dd-mm-yyyy):

- Sex
 - Male
 - Female

- Education
 - Primary school
 - Middle school
 - High school
 - Bachelor's degree
 - Master's degree
 - Other educational degrees

- Do you usually need to be accompanied when you attend the clinic?
 - No
 - Yes, by a family member that lives in your household
 - Yes, by a caregiver who does not live in your household

Section 2

Evaluation of phone follow- up visit

Please answer the short multiple-choice questions below by tick only one box for each question.

Please indicate the extent to which you agree / disagree with the following statements.

1. I am very anxious about my health in this emergency situation due to COV-SARS-2.
 - I strongly agree
 - I agree

- I strongly disagree
- I disagree
- I neither agree nor disagree

2. I look forward to the periodic follow-up visits to feel relief.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

3. Before the interview, I thought it would be easy to have a phone follow-up consultation.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

4. During the follow-up phone call, I could clearly understand the doctor's advice/recommendations.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

5. During the follow-up phone call, I felt that the doctor understood my needs.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

6. The follow-up phone call allowed me enough time to clarify everything useful to my situation at the moment.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

7. During the phone call, I had an opportunity to ask questions and ask for clarifications related to my condition.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

8. In the absence of a clear clinical need, I was pleased to be able to avoid going to the hospital for a standard follow-up visit.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

8. In the absence of an urgent clinical need, I would like phone follow-ups in the future instead of going to the hospital.


- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

9. Overall, in comparison with a standard follow-up visit, how satisfied were with the phone call?


- Very satisfied
- Satisfied
- Very disappointed
- Disappointed
- Neither satisfied nor disappointed

Figure S1. Distribution of responses.


Do you usually need to be accompanied when you attend the clinic?




I am very anxious about my health in this emergency situation due to COV-SARS-2.




I look forward to the periodic follow-up visits to feel relief.




Before the interview, I thought it would be easy to have a phone follow-up consultation.




During the follow-up phone call, I could clearly understand the doctor's advice/recommendations.




During the follow-up phone call, I felt that the doctor understood my needs.




The follow-up phone call allowed me enough time to clarify everything useful to my situation at the moment.




During the phone call, I had an opportunity to ask questions and ask for clarifications related to my condition.



In the absence of a clear clinical need, I was pleased to be able to avoid going to the hospital for a standard follow-up visit.



In the absence of an urgent clinical need, I would like phone follow-ups in the future instead of going to the hospital.



Overall, in comparison with a standard follow-up visit, how satisfied were with the phone call?




Table S1. Multivariate analysis of clinical and biological bCS characteristics and survey answers. *P* values of <0.05 were considered statistically significant. Significant values are bold. Chi square test has been used.

	Age	Educational level	Pandemic phase	Residence	Family history of cancer	Personal history of second cancer	Time from diagnosis	Stage	Previous chemotherapy	Time from end of chemotherapy or anti-Her2 therapy	Previous endocrine therapy	Ongoing endocrine therapy	Time from last physical follow-up
Do you usually need to be accompanied when you attend the clinic?	0.030	<0.001	0.789	0.299	0.866	0.101	0.821	0.980	0.244	1.000	0.867	0.203	0.039
Are you anxious about your health in this emergency situation due to COVID-19?	0.845	0.002	0.579	0.746	0.865	0.608	0.007	0.851	0.759	0.117	0.661	0.540	0.934
Do you look forward to the periodic follow-up visits to feel relief?	0.684	0.201	0.670	0.621	0.312	0.068	0.929	0.550	0.839	0.310	0.292	0.048	0.442
Before the interview, do you thought it would be easy to have a phone follow-up consultation?	0.391	0.146	0.513	0.862	0.578	0.250	0.940	0.943	0.911	0.264	0.314	0.541	0.951
During the follow-up phone call, could you clearly understand the doctor's advice/recommendation?	0.735	0.042	0.222	0.777	0.778	0.052	0.169	0.001	0.968	0.086	0.621	0.506	0.779
During the follow-up phone call, did you feel that the doctor understood your needs?	0.242	0.651	0.028	0.280	0.337	0.581	0.978	0.897	0.568	0.048	0.410	0.682	0.940
Did the follow-up phone call allow you enough time to clarify	0.948	0.496	0.274	0.385	0.556	0.502	0.979	0.348	0.562	0.090	0.027	0.455	0.995

everything useful to my situation at the moment?													
During the phone call, did you have an opportunity to ask questions and ask for clarifications related to your condition?	0.966	0.536	0.583	0.338	0.895	0.143	0.668	0.839	0.289	0.037	0.018	0.230	0.959
In the absence of a clear clinical need, were you pleased to be able to avoid going to the hospital for a standard follow-up visit?	0.987	0.081	0.858	0.253	0.585	0.204	0.657	0.835	0.685	0.048	0.661	0.999	0.605
In the absence of an urgent clinical need, would you like phone follow-ups in the future instead of going to the hospital?	0.797	0.189	0.706	0.219	0.664	0.050	0.322	0.156	0.303	0.184	0.481	0.063	0.554
Overall, in comparison with a standard follow-up visit, how satisfied were you with the phone call?	0.423	0.589	0.003	0.881	0.463	0.541	0.082	0.036	0.086	0.102	0.067	0.147	0.884

Original contribution

Electronic medical record-assisted telephone follow-up of breast cancer survivors during the COVID-19 pandemic: a single institution experience.

Valeria Merz^a, Antonella Ferro^a, Enrico Maria Piras^b, Alberto Zanutto^b, Orazio Caffo^a, Carlo Messina^{a*}.

^aDepartment of Medical Oncology, Santa Chiara Hospital, Trento, Italy; ^bCentre for Information and Communication Technology, Bruno Kessler Foundation, Trento, Italy.

***Corresponding author:** Department of Medical Oncology, Santa Chiara Hospital, Largo Medaglie d'Oro 9, 38122 Trento, Italy. Tel. +39-3339540076. E-mail:

carlo.messina@apss.tn.it

Formatted: Default Paragraph Font

Formatted: Default Paragraph Font

Acknowledgements: The authors would like to thank all of the patients and their families for participating in this study and for their collaboration during the COVID-19 pandemic.

Running head: Telephone follow-up of breast cancer survivors in COVID-19 pandemic.

ABSTRACT

Background: The COVID-19 outbreak rapidly became a public health emergency and led to radical changes in patient management. From the start of the pandemic, we used electronic medical record-assisted telephone follow-up (E-TFU) of cancer survivors (CS) in order to minimise hospital exposure. The aim of this prospective study was to assess how breast cancer survivors (bCS) perceived E-TFU.

Methods: A 15-item [questionnaire survey](#) was e-mailed to bCS who had been managed with E-TFU. The responses were measured using Likert-like scales and were correlated with the main characteristics of the bCS using Pearson's test.

Results: One hundred and thirty-seven out of 343 bCS (40%) completed the [questionnaire survey](#) between 9 March and 2 June 2020. Their median age was 59 years. Although 80.3% of bCS were satisfied with E-TFU, only 43.8% would like to have E-TFU in the future.

A low educational level was correlated with higher COVID-19-related anxiety ($P=0.025$). An older age ($P=0.002$) and a low educational level ($P<0.0001$) were correlated with the need to be accompanied to reach the hospital. A personal history of second cancer was inversely correlated with understanding medical advice ($P=0.015$) and the expectation of feeling relief after a follow-up visit ($P=0.0027$). Furthermore, the pandemic phase 2 was correlated with satisfaction with E-TFU ($P=0.010$).

Conclusion: E-TFU was an important means of avoiding hospital contacts during the COVID-19 pandemic, and the majority of bCS in the survey were satisfied with this procedure. Further studies are needed to investigate the implementation of telemedicine even outside an emergency situation.

INTRODUCTION

Formatted: English (United States)

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was a public health emergency before the World Health Organisation declared it to be a pandemic on 11 March 2020 [1]. First China, and then (by the end of February 2020) Italy experienced the rapid and uncontrolled spread of the virus, and a steep increase in the number of new cases and deaths [2], with recorded lethality being higher in Italy than in China (9% vs 4.3%) [3, 4]. Although the severity of the illness and the risk of death seem to be associated with old age and pre-existing co-morbidities such as cardiopulmonary disease, diabetes and immunodepression, cancer patients and cancer survivors (CS) may be additional high-risk categories [5, 6]. A cohort study of 928 patients from the USA, Canada and Spain with active or previous cancer (45% of the total population) and confirmed SARS-CoV-2 infection entered in the database of the COVID-19 and Cancer Consortium (CCC19) revealed a high 30-day all-cause mortality rate of 13% [7].

Italian lockdown comprised two consecutive phases. The phase 1 started on 9 March 2020 and consisted of absolute prohibition of leaving home except for going to work or other valid reasons (e.g buy essential goods, go to the hospital) [8]. The phase 2 lasted from 4 May to 1 June 2020 and opened up the chance to visit relatives within the own region and do physical activity outdoor. In both the phases almost all stores, cafes and restaurants were closed.

Given that hospitals were considered places at risk of spreading the infection, there was a strong desire to minimise the presence of cancer patients by introducing new telemedicine strategies for follow-up (FU) examinations. This clearly requires robust information technology support in order to allow clinicians to retrieve a record of a patient's clinical history easily and rapidly. Since June 2000, our oncology unit has been using a web-based electronic medical record (EMR) to collect all of the clinical data, laboratory test results, and the findings of imaging examinations and pathology reports relating to each of our patients [9]. This proved to be invaluable when we decided to replace

standard FU visits with EMR-assisted telephone follow-up (E-TFU) interviews for all cancer survivors (CS) at the beginning of the COVID-19 pandemic.

The aim of this prospective study was to assess how E-TFU is perceived by breast CS (bCS), who represent the large majority of the patients followed up at our unit.

MATERIAL AND METHODS

From 9 March 2020 (the start of the Italian government's phase 1 of the COVID-19 pandemic), we switched our in-person follow-up visits to E-TFU, exploiting our web-based EMR that collects the entire medical history of patients and enables to look at the laboratory test results, imaging and pathology reports, and all medical consultations performed in our region. For the purpose of the present study, we identified all of the consecutive bCS who underwent E-TFU until 2 June 2020 (the end of phase 2) with no evidence of active disease. Previous chemotherapy or biological therapy and previous or ongoing endocrine therapy were permitted.

We collected data of bCS relating to their age, sex and educational level; their personal history of a second cancer (previous breast cancer or other tumor types) and family history of cancer; the dates of diagnosis and surgery; the molecular subtype of the tumour; exposure to chemotherapy in a neoadjuvant or adjuvant setting; exposure to endocrine therapy; the duration of FU; and pre-existing co-morbidities.

All bCS providing an e-mail address received a 15-item [questionnairesurvey](#) covering demographic information, COVID-19 or breast cancer-related anxiety, satisfaction with the E-TFU, and willingness to accept E-TFU in the future for non-emergency situations. The [questionnairesurvey](#) was prepared by EMP and AZ, and an English translated version is reported in the Appendix. Five-point ordinal Likert-like scales were used to rate the extent of agreement or disagreement with the multiple statements [10]. A score from 1 to 5, corresponding to the five possible answer options, describes an increasing level of agreement. Older or less tech-savvy patients were encouraged to ask for support of other family members, that if necessary have been directly contacted.

The respondents gave their informed consent to completing the [questionnairesurvey](#), the answers to which were analysed by VM and CM and matched with the clinical data retrieved from the web-based EMR.

The primary aim of this prospective study was to assess the acceptance of the E-TFU. The secondary aims were to assess the respondents' perception of their understanding of the medical advice received during the E-TFU, their satisfaction with the possibility of asking for clarifications, and their reaction to the possible future use of the system in a non-emergency setting.

The continuous variables are expressed as median values and ranges, and the categorical variables as absolute numbers and percentages. The differences in the baseline characteristics of the respondents and non-respondents to the [questionnairesurvey](#) were analysed using Fisher's exact test and the Mann-Whitney U test. The distribution of the responses evaluated with Likert-like scales and possible correlations with the bCS demographic and clinical characteristics were compared [at uni- and multivariate analyses](#) using Pearson's two-sided test and Chi square test [11]. The statistical analyses were made using SPSS, version 25.0 (IBM Corporation, Chicago, IL, USA).

RESULTS

Three hundred and forty-three bCS underwent E-TFU between 9 March and 2 June 2020, among them 78 patients declared to have not an e-mail address for the survey. The [questionnairesurvey](#) was completed by 137 (~~51.648.4~~%) of surveyed). Table 1 shows the characteristics of the respondents and non-respondents. The median age of the respondents was 59 years (range 34-86). The majority of respondents (66%) completed the [questionnairesurvey](#) during phase 1 of the COVID-19 pandemic. The median duration of FU from the date of diagnosis was 46 months (range 2-134 months). About two-thirds of the respondents had a high school diploma or university degree. Ninety-six (70%) had a positive family history of cancer, and 27 (20%) a personal history of a second cancer: 20 had a previous breast cancer and the other 7 had different types of cancer (e.g. colon or renal cancer). Forty-three percent had pre-existing co-morbidities. Sixty-five (47%) received chemotherapy in a neoadjuvant or adjuvant setting. The majority (83%) had received

adjuvant endocrine therapy, which was ongoing in 64%. The median time from the end of chemotherapy and the PFU was 42 months (range 5-208 months).

Most of the bCS (80%) were capable of reaching the hospital autonomously for standard FU visits. About 60% lived in the suburbs, and 40% in the city centre. The median time from the last standard FU visit to the E-TFU was six months (range 1-42).

Nearly 64% of the respondents suffered from COVID-19-related anxiety about their health, the majority of whom (83%) were looking forward to the FU visit to feel relief (Supp. Fig. S1). Before the E-TFU, 68% thought that it would have been easy to undergo E-TFU instead of standard FU. Almost all of the respondents (97.1%) believed that they had understood the medical advice received during the E-TFU, and 93.4% agreed that the E-TFU doctors had understood their needs, 89.8% were satisfied with the duration of the phone call, and 90.5% agreed that they had had an opportunity to ask for clarifications. Ninety-two percent agreed with the medical decision to replace the standard FU visit with E-TFU in absence of a real sign of emergency in order to minimise hospital exposure, but only 43.8% said that they would like to have a future E-TFU in a non-emergency situation. The latter subgroup of patients had a median age of 62 years and among them 10% had a previous cancer, the majority (68.3%) had an early stage breast cancer (0 or I stage), 40% had received chemotherapy and 80% had received or was receiving endocrine therapy. Overall, 80.3% of the respondents were satisfied when comparing E-TFU with a standard FU visit. Tables 2 and S1 show the correlations between the patients' clinical characteristics and their answers to the [questionnaire survey](#).

At the univariate analysis a low educational level was correlated with higher COVID-19-related anxiety ($P=0.025$). An older age ($P=0.002$) and a low educational level ($P<0.0001$) were correlated with the need to be accompanied to reach the hospital. A personal history of second cancer was inversely correlated with understanding medical advice ($P=0.015$) and the expectation of feeling relief after a FU visit ($P=0.0027$). Furthermore, the pandemic phase 2 was correlated with

satisfaction with E-TFU ($P=0.010$). No clinical characteristics were correlated with the willing to undergo E-TFU in the future.

DISCUSSION

Italy was the first European country to be hit by the COVID-19 outbreak which, as of 1 June 2020, had led to 233.607 confirmed cases and 32.235 deaths [12,13]. The unexpected and rapid spread of SARS-CoV-2 left many oncologists facing unprecedented challenges.

Liang et al. first showed that cancer patients were at increased risk of SARS-CoV-2 infection and the severe consequences that often require admission to an intensive care unit [6]. This led Italian Association of Medical Oncology (AIOM) and the Boards of Academic Oncologists (COMU) and Oncology Unit Directors (CIPOMO) to make specific recommendations concerning cancer patients receiving active treatments during the outbreak, CS undergoing FU, and the hospital visits of patients and their caregivers [14]. Oncologists were invited to consider delaying active treatment administration in responders or administering different schedules in order to minimise hospital visits, and the outpatients scheduled for treatment who had respiratory symptoms or fever were to be triaged by nurses before hospital admission in order to prevent contact with other patients. The admission of family members or patients' caregivers was to be prohibited, except in the case of patients who seriously needed assistance.

A number of hospitals adopted E-TFU or the on-line exchange of clinical documentation instead of standard consultancy in order to reassure CS by avoiding hospital exposure except in the case of an emergency or laboratory and/or imaging signs of recurrent cancer [15]. In this context, it is worth noting that a recent Cochrane review has shown the effectiveness of telephone symptom management and highlighted the need for further research [16].

Accordingly, during pandemic we switched all our follow-up visits to telemedicine exploiting the availability of a web-based EMR, which we used since June 2000 to manage our cancer patients

and which was previously described [9]. Clearly the availability of a robust EMR is crucial in supporting telemedicine activities allowing clinicians full retrieval of patients' clinical data.

All of our CS were managed by means of E-TFU during the pandemic, but this study only considers bCS because they represent the vast majority of the CS undergoing FU at our unit. This allows us to analyse a homogeneous population but clearly limits the applicability of our results to different cancer populations, since the cancer type diagnosis could impact on preference for surveillance modalities [17].

Cancer-related fatigue and cognitive disorders are distressing and highly prevalent long-term side effects among bCS, especially those who have received chemotherapy [18, 19], and so it was important to assess whether COVID-19 was a further cause of anxiety and whether E-TFU was a sufficiently good means of offering them reassurance and relief from the distress caused by the risk of infection due to hospital exposure and the risk of cancer recurrence.

Most of the respondents to our [questionnairesurvey](#) agreed with the use of E-TFU instead of a standard FU visit, but 48.9% disagreed with the future use of E-TFU in non-emergency situations. The majority believed they had understood the doctors' advice received during E-TFU, and were satisfied with the time and the opportunity to ask for clarifications. These findings indicate that E-TFU was a useful strategy during the COVID-19 outbreak and that it will probably be well accepted by bCS in the event of further waves of the pandemic. Although the majority of patients would prefer standard consultations in non-emergency situations, 43.8% agreed that they would be willing to undergo E-TFU in the future. The difference between these two aspects might suggest that many patients only need to get used to this novel visit modality. ~~Anyway, patients who would accept to be followed up remotely in a non-emergency situation represent a significant subgroup and deserves further evaluations.~~

It is clear that the acceptance and compliance about an innovative approach, that switches the traditional in-person visits into a telephone-based contact, might be not so immediate and a not negligible number of patients considers as not acceptable this change outside of an emergency

scenario. Thus, in our opinion, the rate of patients indicating an interest in maintaining such approach in the future is not so trivial and conversely it could be surprising to find significantly higher rates after only one first experience.

Anyway, patients that would accept to be visited remotely in a non-emergency situation represent a significant subgroup and deserve further evaluations.

It is difficult to explain the relatively low level of overall satisfaction with E-TFU. Although all of the dimensions related to satisfaction indicated a much higher approval rate (89,8% approved of the duration of E-TFU; 90.5% were satisfied with the opportunity to ask for clarifications; 97% understood the medical advice received; and 93.4% felt that the doctors understood their needs), “only” 80.3% declared that they were satisfied in general. More research is required to investigate whether there are other relevant dimensions not addressed by the survey or whether there are some needs that are not met by the present form of E-TFU.

Interestingly, E-TFU has not only prevented patient access to the hospital during the pandemic, but has also allowed physicians with risky conditions working from home.

Almost all respondents affirmed that they had understood medical information during the E-TFU. Several studies report that the patient self-assessment of comprehension during a medical visit differs from a more objective assessment [20]. Obviously, this is a limitation intrinsic to the verbal communication, not confined to telephone-based visits. However, the absence of the non-verbal communication in E-TFU could increase the gap between medical communication and patient comprehension, that could be filled with video visits [21].

This study has a number of limitations related to the heterogeneity of the patients' characteristics, the duration of FU and the differences in the exposure to chemotherapy or endocrine therapy. The two groups of respondents and non-respondents had a similar number of patients by stage and endocrine treatment, but the respondents were characterised by greater exposure to chemotherapy (47.4 % vs 28.4 %, $P<0.001$) and a larger proportion of subjects with a positive family and personal history of cancer (respectively 70% vs 58%, $P=0.028$; and 19.7% vs 9.2%, $P=0.009$).

Another critical issue was the poor response rate (48.451.6%), which was partially due to age and the fact that not all of our CS have an e-mail address. Although failure to respond to a satisfaction survey might itself represent a signal of poor satisfaction with the offered type of FU, we cannot exclude that by contrast the most unsatisfied patients answered our survey. In fact, in presenting the survey to the patients, we emphasized the importance to give their own opinion through the completion of the [questionnairesurvey](#), even more in the case of concerns regarding the E-TFU.

Moreover, we decided not to reach out the non-respondents by a new phone contact in order to do avoid possible evaluation biases.

Furthermore, we only considered bCS, and further studies are needed before generalizing our findings to all CS. Several studies reported that telematic visits could replace in-person visits in different chronic pathologies, demonstrating a similar efficacy [22, 23, 24, 25]. Few studies investigated the use of telemedicine for cancer surveillance. A previous study reported a good acceptance of telephone FU by cured breast cancer patients without physical or psychological disadvantage compared to hospital FU [26]. A recent survey on cancer patients in surveillance after curative surgery showed that roughly 50% patients preferred to receive news about “normal” results electronically (through an electronic tool or by e-mail) while the majority of them preferred a direct conversation by in-office appointments or phone calls in the case of abnormal results [17].

Another important limitation of our study is that psychometric properties of the scales used in the [questionnairesurvey](#) were not previously validated. Lastly, since the analysis included a small number of patients our results and the interpretation of uni- and multivariable analyses should be cautiously considered.

Nevertheless, to the best of our knowledge, this is the first report of the use of the EMR-based E-TFU of bCS during the COVID-19 pandemic, and the findings suggest a need for further investigations into the reasons behind the preference for standard face-to-face FU visits in order to identify strategies that would increase the willingness of bCS to undergo E-TFU. For example, studies of different clinical conditions have shown show that patients prefer FU video calls over

phone calls [27, 28], which suggests that a small investment in the integration of existing technologies could provide significant benefits. A review of studies of patients with chronic diseases (who have much in common with bCS) has found that video consultations can be considered an appropriate means of confronting the emergency due to COVID-19 [29].

Moreover, the idea of “emergency” requires further investigation in order evaluate whether it is only strictly applicable to life-threatening situations such as a pandemic or could also apply to less serious events (e.g. avoiding the hospital during the influenza season) or personal limitations such as the impossibility of attending a hospital appointment because of a broken leg or a malfunctioning car.

CONCLUSIONS

E-TFU proved to be an important means of avoiding hospital contacts during the COVID-19 pandemic, and the majority of our responding bCS were satisfied with the procedure. However, the number of bCS willing to have E-TFU in non-emergency situations suggests that routine E-TFU needs further investigation, at least in a subset of CS. Prospective randomised trials are warranted to assess the clinical reliability of E-TFU in comparison with standard FU visit before implementing telemedicine in everyday clinical practice. Furthermore, we only considered bCS, and further studies are needed before our findings can be generalised to all CS.

REFERENCES

1. The World Health Organization (WHO). Available at: ~~<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>~~. Accessed ~~22 March 2020~~<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. Accessed 22 March 2020.
2. Lazzarini M, Putoto G. COVID-19 in Italy: momentous decisions and many uncertainties. *Lancet Glob Health* 2020 ;8(5):e641- e642.
3. The World Health Organization (WHO). Health emergency dashboard. Available at: <https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd>. Accessed 19 March 2020.
4. <http://www.protezionecivile.gov.it/attivita-rischi/rischio-sanitario/emergenze/coronavirus>
5. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395: 1054-1062.
6. Liang W, Guan W, Chen R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020; 21: 335-337.
7. Kuderer NM, Choueiri TK, Shah DP et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet*. 2020;S0140-6736(20)31187-9
8. <http://www.governo.it/it/coronavirus-misure-del-governo>
9. Galligioni E, Berloffia F, Caffo O et al. Development and daily use of an electronic oncological patient record for the total management of cancer patients: 7 years' experience. *Ann Oncol*. 2009;20(2):349- 352.
10. Sullivan GM, Artino AR Jr. Analyzing and interpreting data from likert-type scales. *J Grad Med Educ*. 2013;5(4):541- 542.
11. Wilson EB, Hilferty MM. The Distribution of Chi-Square. *Proceedings of the National Academy of Sciences of the United States of America*. 1931;17(12):684-8.

Field Code Changed

Formatted: Default Paragraph Font

Formatted: Default Paragraph Font

12. Istituto Superiore di sanità. Available: <https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati>.
13. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next?. *Lancet*. 2020;395(10231):1225- 1228.
14. Rischio infettivo da Coronavirus COVID-19: indicazioni per l'Oncologia da parte del Presidente AIOM, del presidente eletto AIOM, del Presidente CIPOMO e del Presidente COMU. Available at https://www.aiom.it/wa-content/uploads/2020/03/20200313_COVID19_indicazioni_AIOM-CIPOMO-COMU.pdf
15. Tagliamento M, Lambertini M, Genova C et al. Call for ensuring cancer care continuity during COVID-19 pandemic. *ESMO Open*. 2020;5(3):e000783.
16. Ream E, Hughes AE, Cox A et al. Telephone interventions for symptom management in adults with cancer. *Cochrane Database Syst Rev*. 2020;6:CD007568. Published 2020 Jun 2.
17. Onuma AE, Palmer Kelly E, Chakedis J et al. Patient preferences on the use of technology in cancer surveillance after curative surgery: A cross-sectional analysis. *Surgery* 2019 Apr;165(4):782-788
18. Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatments. *Nat Rev Clin Oncol*. 2014;11(10):597- 609
19. Joly F, Lange M, Dos Santos M et al. Long-Term Fatigue and Cognitive Disorders in Breast Cancer Survivors. *Cancers* 2019, 11, 1896.
20. Carey M, Herrmann A, Hall A et al. Exploring health literacy and preferences for risk communication among medical oncology patients. *PLoS One*. 2018 Sep 18;13(9):e0203988
21. Powell RE, Henstenburg JM, Cooper G et al. Patient Perceptions of Telehealth Primary Care Video Visits. *Ann Fam Med* 2017 May;15(3):225-229
22. Armstrong AW, Ford AR, Chambers CJ et al. Online Care Versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial. *J Invest Dermatol* 2019 May;139(5):1037-1044

23. Armstrong AW, Chambers CJ, Maverakis E et al. Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial. *JAMA Netw Open* 2018 Oct 5;1(6):e183062
24. Portnoy JM, Waller M, De Lurgio S et al. Telemedicine is as effective as in-person visits for patients with asthma. *Ann Allergy Asthma Immunol* 2016 Sep;117(3):241-5
25. Inglis SC, Clark RA, McAlister FA et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. *Cochrane Database Syst Rev* 2010 Aug 4;(8):CD007228
26. Beaver K, Tysver-Robinson D, Campbell, Twomey MM et al. Comparing hospital and telephone follow-up after treatment for breast cancer: randomised equivalence trial. *BMJ* 2009 Jan 14;338:a3147
27. Kim S S, Darwish S, Lee S A et al. A randomized controlled pilot trial of a smoking cessation intervention for US women living with HIV: telephone-based video call vs voice call. *International journal of women's health* 2018, 10, 545
28. Cohen F, McCarthy J, Gribko et al. Abstract WP329: Video Conferencing is the Preferred Method for Follow-up Communication for Post-hospital Stroke Patients. *Stroke* 2016, 47(suppl_1), AWP329-AWP329.
29. Greenhalgh T, Wherton J, Shaw S et al. Video consultations for covid-19. *BMJ* 2020;368:m998

Formatted: Default Paragraph Font

Formatted: Default Paragraph Font

Formatted: Default Paragraph Font

Formatted: Default Paragraph Font

Table 1. Baseline clinical characteristics of the respondents and non-respondents.

	Respondents n =137	Non-respondents n =206	P value
Sex			
Female	136 (99.2%)	204 (99.0%)	0.454
Male	1 (0.7%)	2 (1.0%)	
Median age (years)	59 (34-86)	63 (34-89)	0.028*
Family history of cancer	96 (70.1%)	122 (58.9%)	0.028*
Personal history of a second cancer	27 (19.7%)	19 (9.2)	0.009*
Residence			
City centre	55 (40.1%)	90 (43.5%)	0.577
Suburbs	82 (59.9%)	116 (56%)	

Stage			
0	2 (1.5%)	2 (1%)	0.380
I	71 (51.8%)	102 (49.3%)	
II	45 (32.8%)	82 (39.6%)	
III	14 (10.2%)	20 (9.7%)	
IV	2 (1.5%)	0	
Molecular subtype			0.623
Luminal A	74 (54%)	124 (59.6%)	
Luminal B/HER2-	27 (19.7%)	38 (18.3%)	
Luminal B/HER2+	15 (10.9%)	21 (10.1%)	
HER2+	6 (4.4%)	9 (4.3%)	
Triple negative	13 (9.5%)	12 (5.8%)	
Previous surgery	137 (100%)	206 (100%)	-
Previous chemotherapy	65 (47.4%)	59 (28.4%)	0.000*
Previous endocrine therapy	113 (82.5%)	174 (83.7%)	0.656
Ongoing endocrine therapy	88 (64.2%)	131 (63.3%)	1.000
Pandemic phase			0.010*
1	91 (66.5%)	108 (52.5%)	
2	46 (33.5%)	98 (47.6%)	

*statistically significant

Table 2. Correlation between clinical and biological bCS characteristics at the univariate analysis. *P* values are reported. *P* values of <0.05 were considered statistically significant. Correlation coefficients are reported in brackets. Significant values are bold.

Formatted: Font: Italic

	Age	Educational level	Pandemic phase	Residence	Family history of cancer	Personal history of second cancer	Time from diagnosis	Stage	Previous chemotherapy	Time from end of chemotherapy or anti-Her2 therapy	Previous endocrine therapy	Ongoing endocrine therapy	Time from last physical follow-up
Do you usually need to be accompanied when you attend the clinic?	0.002 (0.256)	<0.001 (-0.416)	0.628 (-0.042)	0.123 (0.132)	0.911 (-0.010)	0.178 (0.116)	0.646 (-0.040)	0.660 (0.038)	0.112 (-0.136)	0.666 (-0.055)	0.684 (0.042)	0.874 (0.053)	0.518 (-0.017)
Are you anxious about your health in this emergency situation due to COVID-19?	0.447 (0.065)	0.025 (-0.191)	0.659 (-0.038)	0.750 (-0.027)	0.479 (-0.061)	0.208 (-0.108)	0.832 (-0.018)	0.663 (-0.008)	0.306 (-0.088)	0.770 (0.037)	0.158 (-0.121)	0.465 (-0.063)	0.931 (-0.007)
Do you look forward to the periodic follow-up visits to feel relief?	0.641 (-0.016)	0.295 (-0.128)	0.808 (-0.007)	0.294 (0.104)	0.855 (0.020)	0.027 (-0.189)	0.276 (-0.094)	0.476 (-0.084)	0.649 (0.039)	0.796 (-0.033)	0.834 (-0.014)	0.275 (0.052)	0.103 (-0.070)
Before the interview, do you thought it would be easy to have a phone follow-up consultation?	0.658 (-0.038)	0.056 (0.158)	0.877 (0.013)	0.355 (-0.088)	0.151 (-0.102)	0.147 (-0.115)	0.946 (-0.006)	0.772 (-0.060)	0.369 (-0.083)	0.286 (0.135)	0.310 (0.087)	0.875 (0.014)	0.682 (0.030)
During the follow-up phone call, could you clearly understand the doctor's advice/recommendation?	0.063 (-0.159)	0.055 (0.164)	0.115 (0.135)	0.526 (-0.055)	0.363 (-0.078)	0.015 (-0.207)	0.569 (0.049)	0.979 (0.002)	0.924 (0.008)	0.728 (0.044)	0.266 (0.096)	0.333 (0.083)	0.208 (0.108)
During the follow-up phone call, did you feel that the doctor understood your needs?	0.463 (-0.070)	0.545 (0.052)	0.062 (0.160)	0.309 (-0.088)	0.572 (-0.049)	0.424 (-0.069)	0.745 (-0.028)	0.798 (-0.022)	0.263 (-0.096)	0.946 (-0.009)	0.222 (0.105)	0.477 (0.061)	0.611 (-0.044)
Did the follow-up phone call allow you enough time to clarify everything useful to my situation at the	0.305 (-0.088)	0.315 (0.087)	0.063 (0.159)	0.094 (-0.143)	0.723 (0.031)	0.668 (-0.037)	0.699 (0.033)	0.525 (-0.055)	0.581 (-0.048)---	0.510 (0.084)	0.413 (0.071)	0.555 (0.051)	0.390 (0.074)

moment?													
During the phone call, did you have an opportunity to ask questions and ask for clarifications related to your condition?	0.173 (-0.117)	0.280 (0.093)	0.141 (0.127)	0.155 (-0.122)	0.546 (0.052)	0.106 (-0.139)	0.173 (-0.117)	0.324 (-0.086)	0.748 (0.028)	0.531 (-0.080)	0.133 (0.129)	0.107 (0.138)	0.721 (-0.031)
In the absence of a clear clinical need, were you pleased to be able to avoid going to the hospital for a standard follow-up visit?	0.759 (0.026)	0.374 (-0.077)	0.956 (-0.005)	0.985 (-0.002)	0.170 (-0.118)	0.201 (-0.110)	0.508 (-0.057)	0.370 (-0.078)	0.517 (-0.056)	0.811 (-0.030)	0.572 (-0.049)	0.976 (0.003)	0.305 (0.088)
In the absence of an urgent clinical need, would you like phone follow-ups in the future instead of going to the hospital?	0.477 (0.061)	0.271 (-0.095)	0.159 (0.121)	0.827 (-0.019)	0.639 (-0.040)	0.0112 (-0.136)	0.852 (-0.016)	0.059 (-0.164)	0.082 (-0.149)	0.530 (0.080)	0.795 (0.022)	0.479 (-0.061)	0.304 (0.088)
Overall, in comparison with a standard follow-up visit, how satisfied were you with the phone call?	0.968 (0.003)	0.567 (-0.049)	0.010 (0.219)	0.818 (-0.020)	0.311 (-0.087)	0.133 (-0.129)	0.856 (0.016)	0.840 (-0.018)	0.111 (-0.137)---	0.280 (-0.137)	0.095 (0.143)	0.284 (0.092)	0.525 (0.055)

Appendix

Web-based electronic medical record-assisted phone follow-up during the COVID-19 pandemic: a survey.

Dear Sir/Madam,

As you know, the coronavirus epidemic forced us to use the phone to carry out our periodic follow-up evaluations for the first time.

It is important for us to know what you think of this experience, and whether you found it positive and satisfactory in terms of the various aspects covered by your interview with the doctor.

For this reason, we are sending you a short [questionnaire survey](#) in order to evaluate your agreement with this method of contact.

None of the questions relate to sensitive information. Your answers will be anonymised and then analysed in aggregate form in such a way as to make it impossible to trace them back to you.

If you are willing to respond to the [questionnaire survey](#), please click on the link at the bottom of this e-mail.

In the case of any difficulty, do not hesitate to contact us at the following e-mail addresses: valeria.merz@apss.tn.it or carlo.messina@apss.tn.it.

Thank you once again for your contribution.

The doctors of the Oncology Unit, Santa Chiara Hospital, Trento, Italy.

Section 1

Thank you very much for agreeing to participate in this survey. Completing the [questionnaire survey](#) only takes a few minutes, but it will allow us to evaluate the phone follow-up visit. The data will only be used for research purposes, and will be processed in aggregate form in order to guarantee the privacy of the respondents.

- Date of birth (dd-mm-yyyy):

- Sex
 - Male
 - Female

- Education
 - Primary school
 - Middle school
 - High school
 - Bachelor's degree
 - Master's degree
 - Other educational degrees

- Do you usually need to be accompanied when you attend the clinic?
 - No
 - Yes, by a family member that lives in your household
 - Yes, by a caregiver who does not live in your household

Section 2

Evaluation of phone follow- up visit

Please answer the short multiple-choice questions below by tick only one box for each question.

Please indicate the extent to which you agree / disagree with the following statements.

1. I am very anxious about my health in this emergency situation due to COV-SARS-2.

- I strongly agree
- I agree

- I strongly disagree
- I disagree
- I neither agree nor disagree

2. I look forward to the periodic follow-up visits to feel relief.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

3. Before the interview, I thought it would be easy to have a phone follow-up consultation.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

4. During the follow-up phone call, I could clearly understand the doctor's advice/recommendations.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

5. During the follow-up phone call, I felt that the doctor understood my needs.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

6. The follow-up phone call allowed me enough time to clarify everything useful to my situation at the moment.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

7. During the phone call, I had an opportunity to ask questions and ask for clarifications related to my condition.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree

8. In the absence of a clear clinical need, I was pleased to be able to avoid going to the hospital for a standard follow-up visit.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree


8. In the absence of an urgent clinical need, I would like phone follow-ups in the future instead of going to the hospital.

- I strongly agree
- I agree
- I strongly disagree
- I disagree
- I neither agree nor disagree


9. Overall, in comparison with a standard follow-up visit, how satisfied were with the phone call?

- Very satisfied
- Satisfied
- Very disappointed
- Disappointed
- Neither satisfied nor disappointed


Figure S1. Distribution of responses.




I am very anxious about my health in this emergency situation due to COV-SARS-2.




I look forward to the periodic follow-up visits to feel relief.




Before the interview, I thought it would be easy to have a phone follow-up consultation.




During the follow-up phone call, I could clearly understand the doctor's advice/recommendations.




During the follow-up phone call, I felt that the doctor understood my needs.




The follow-up phone call allowed me enough time to clarify everything useful to my situation at the moment.




During the phone call, I had an opportunity to ask questions and ask for clarifications related to my condition.



In the absence of a clear clinical need, I was pleased to be able to avoid going to the hospital for a standard follow-up visit.



In the absence of an urgent clinical need, I would like phone follow-ups in the future instead of going to the hospital.



Overall, in comparison with a standard follow-up visit, how satisfied were with the phone call?




Table S12. Multivariate analysis of clinical and biological bCS characteristics and [questionnaire survey](#) answers. *P* values of <0.05 were considered statistically significant. Significant values are bold. [Chi square test has been used.](#)

	Age	Educational level	Pandemic phase	Residence	Family history of cancer	Personal history of second cancer	Time from diagnosis	Stage	Previous chemotherapy	Time from end of chemotherapy or anti-Her2 therapy	Previous endocrine therapy	Ongoing endocrine therapy	Time from last physical follow-up
Do you usually need to be accompanied when you attend the clinic?	0.030	<0.001	0.789	0.299	0.866	0.101	0.821	0.980	0.244	1.000	0.867	0.203	0.039
Are you anxious about your health in this emergency situation due to COVID-19?	0.845	0.002	0.579	0.746	0.865	0.608	0.007	0.851	0.759	0.117	0.661	0.540	0.934
Do you look forward to the periodic follow-up visits to feel relief?	0.684	0.201	0.670	0.621	0.312	0.068	0.929	0.550	0.839	0.310	0.292	0.048	0.442
Before the interview, do you thought it would be easy to have a phone follow-up consultation?	0.391	0.146	0.513	0.862	0.578	0.250	0.940	0.943	0.911	0.264	0.314	0.541	0.951
During the follow-up phone call, could you clearly understand the doctor's advice/recommendation?	0.735	0.042	0.222	0.777	0.778	0.052	0.169	0.001	0.968	0.086	0.621	0.506	0.779
During the follow-up phone call, did you feel that the doctor understood your needs?	0.242	0.651	0.028	0.280	0.337	0.581	0.978	0.897	0.568	0.048	0.410	0.682	0.940
Did the follow-up phone call allow you enough time to clarify	0.948	0.496	0.274	0.385	0.556	0.502	0.979	0.348	0.562	0.090	0.027	0.455	0.995

everything useful to my situation at the moment?													
During the phone call, did you have an opportunity to ask questions and ask for clarifications related to your condition?	0.966	0.536	0.583	0.338	0.895	0.143	0.668	0.839	0.289	0.037	0.018	0.230	0.959
In the absence of a clear clinical need, were you pleased to be able to avoid going to the hospital for a standard follow-up visit?	0.987	0.081	0.858	0.253	0.585	0.204	0.657	0.835	0.685	0.048	0.661	0.999	0.605
In the absence of an urgent clinical need, would you like phone follow-ups in the future instead of going to the hospital?	0.797	0.189	0.706	0.219	0.664	0.050	0.322	0.156	0.303	0.184	0.481	0.063	0.554
Overall, in comparison with a standard follow-up visit, how satisfied were you with the phone call?	0.423	0.589	0.003	0.881	0.463	0.541	0.082	0.036	0.086	0.102	0.067	0.147	0.884